Atlanta, GA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced today an expansion of its existing relationship with a prominent healthcare system that manages 80+ facilities throughout the United States. The health system has further expanded its use of RevID. The Company also announced that it has now exceeded its previously stated goal of $17 million of booked SaaS ACV by the end of its fiscal 2022.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“We are pleased that this key healthcare provider continues to expand utilization of our novel RevID solution and thrilled that our sales team was able to execute on its SaaS bookings goals thus far in fiscal 2022” stated Ben Stilwill, President, Streamline Health. “We look forward to continued growth as a result of our mission to ensure that our nation’s healthcare providers are paid for the care they provide.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.59 |
| Daily Volume: | 0 |
| Market Cap: | US$15.330M |
December 18, 2024 December 16, 2024 October 08, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
